A daily pill would be easier to use and, because it would be cheaper to manufacture, could possibly lower patient costs, expert say
Based on the typical UK regulatory pathway, the most realistic timeline is: Late 2026 / early 2027: Eli Lilly expected to submit regulatory filings to the FDA and MHRA following completion of the remaining TRIUMPH Phase 3 readouts Late 2027 to mid-2028: Possible MHRA marketing authorisation, allowing private UK prescribing 2028 to 2029 onwards: Possible NHS availability following a NICE technology appraisal and NHS commissioning decisions Timelines may differ across the four UK nations, as Scotland, Wales, and Northern Ireland assess medicines separately through the Scottish Medicines Consortium (SMC), All Wales Medicines Strategy Group (AWMSG), and the Department of Health Northern Ireland respectively
5, 9 May 2025, pp 450-65,
Based on the available data, the peptide is well tolerated in short-term studies
Its also worth mentioning that while the term availability is used for both, the data will be normalised to a maximum of 100% of available drug, as thats what the user experiences
.webp)
